Novartis Starlix Takes Aim At Diabetes Prevention With 8,000-Patient Study
Novartis will seek a diabetes prevention claim for its type 2 diabetes therapy Starlix with data generated by an 8,000-patient outcomes study.
Novartis will seek a diabetes prevention claim for its type 2 diabetes therapy Starlix with data generated by an 8,000-patient outcomes study.